Kinvard Bio

Executive Summary

Kinvard Bio is a pre-clinical biotechnology company spun out from Harvard University's Myers Lab, pioneering a novel class of broad-spectrum antibiotics called oxepanoprolinamides (OPPs). These compounds target the bacterial ribosome and are designed to overcome antimicrobial resistance, a critical global health threat. The lead candidate, Cresomycin, is being developed for both intravenous and oral administration to treat acute and chronic drug-resistant infections. Preclinical data suggest potent activity against resistant Gram-positive and Gram-negative pathogens. The company is currently advancing Cresomycin through IND-enabling studies and addressing key manufacturing challenges for its novel molecular scaffold. With a strong scientific foundation and a clear unmet need in the antibiotic pipeline, Kinvard Bio represents an early-stage opportunity in the fight against antimicrobial resistance, though it remains pre-revenue and faces typical clinical development risks.

Upcoming Catalysts (preview)

• Q4 2026IND submission for Cresomycin40% success
• Q3 2026Interim preclinical efficacy data in resistant infection models75% success
• Q4 2026Series A funding round or strategic partnership60% success